Drugs / VR-AD-1005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06193408 | Feb → Aug 2024 | cholera | Hunazine Biotech S.L. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VR-AD-1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06193408 ↗ |
| Route | Oral | “oral capsule” NCT06193408 ↗ |